Spontaneous and vaccine-induced clearance of Mus musculus papillomavirus 1 infection

Rosie T. Jiang, Joshua W. Wang, Shiwen Peng, Tsui Chin Huang, Chenguang Wang, Fabiana Cannella, Yung Nien Chang, Raphael P. Viscidi, Simon R.A. Best, Chien Fu Hung, Richard B.S. Roden

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Mus musculus papillomavirus 1 (MmuPV1/MusPV1) induces persistent papillomas in immunodeficient mice but not in common laboratory strains. To facilitate the study of immune control, we sought an outbred and immunocompetent laboratory mouse strain in which persistent papillomas could be established. We found that challenge of SKH1 mice (Crl:SKH1-Hrhr) with MmuPV1 by scarification on their tail resulted in three clinical outcomes: (i) persistent (>2-month) papillomas (~20%); (ii) transient papillomas that spontaneously regress, typically within 2 months (~15%); and (iii) no visible papillomas and viral clearance (~65%). SKH1 mice with persistent papillomas were treated by using a candidate preventive/therapeutic naked-DNA vaccine that expresses human calreticulin (hCRT) fused in frame to MmuPV1 E6 (mE6) and mE7 early proteins and residues 11 to 200 of the late protein L2 (hCRTmE6/mE7/mL2). Three intramuscular DNA vaccinations were delivered biweekly via in vivo electroporation, and both humoral and CD8 T cell responses were mapped and measured. Previously persistent papillomas disappeared within 2 months after the final vaccination. Coincident virologic clearance was confirmed by in situ hybridization and a failure of disease to recur after CD3 T cell depletion. Vaccination induced strong mE6 and mE7 CD8+ T cell responses in all mice, although they were significantly weaker in mice that initially presented with persistent warts than in those that spontaneously cleared their infection. A human papillomavirus 16 (HPV16)-targeted version of the DNA vaccine also induced L2 antibodies and protected mice from vaginal challenge with an HPV16 pseudovirus. Thus, MmuPV1 challenge of SKH1 mice is a promising model of spontaneous and immunotherapydirected clearances of HPV-related disease.

Original languageEnglish
Article numbere00699-17
JournalJournal of Virology
Volume91
Issue number15
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Papillomavirus Infections
Papillomaviridae
Mus musculus
papilloma
Papilloma
Vaccines
vaccines
mice
infection
Human papillomavirus 16
T-lymphocytes
vaccination
Vaccination
DNA Vaccines
recombinant vaccines
T-Lymphocytes
Pseudovirus
calreticulin
warts
electroporation

Keywords

  • DNA vaccines
  • Mouse model
  • Neutralizing antibodies
  • Papillomavirus
  • SKH-1 mice
  • T cells

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Jiang, R. T., Wang, J. W., Peng, S., Huang, T. C., Wang, C., Cannella, F., ... Roden, R. B. S. (2017). Spontaneous and vaccine-induced clearance of Mus musculus papillomavirus 1 infection. Journal of Virology, 91(15), [e00699-17]. https://doi.org/10.1128/JVI.00699-17

Spontaneous and vaccine-induced clearance of Mus musculus papillomavirus 1 infection. / Jiang, Rosie T.; Wang, Joshua W.; Peng, Shiwen; Huang, Tsui Chin; Wang, Chenguang; Cannella, Fabiana; Chang, Yung Nien; Viscidi, Raphael P.; Best, Simon R.A.; Hung, Chien Fu; Roden, Richard B.S.

In: Journal of Virology, Vol. 91, No. 15, e00699-17, 01.08.2017.

Research output: Contribution to journalArticle

Jiang, RT, Wang, JW, Peng, S, Huang, TC, Wang, C, Cannella, F, Chang, YN, Viscidi, RP, Best, SRA, Hung, CF & Roden, RBS 2017, 'Spontaneous and vaccine-induced clearance of Mus musculus papillomavirus 1 infection', Journal of Virology, vol. 91, no. 15, e00699-17. https://doi.org/10.1128/JVI.00699-17
Jiang, Rosie T. ; Wang, Joshua W. ; Peng, Shiwen ; Huang, Tsui Chin ; Wang, Chenguang ; Cannella, Fabiana ; Chang, Yung Nien ; Viscidi, Raphael P. ; Best, Simon R.A. ; Hung, Chien Fu ; Roden, Richard B.S. / Spontaneous and vaccine-induced clearance of Mus musculus papillomavirus 1 infection. In: Journal of Virology. 2017 ; Vol. 91, No. 15.
@article{d4f2a4ed48b84125827f217e443b2f1c,
title = "Spontaneous and vaccine-induced clearance of Mus musculus papillomavirus 1 infection",
abstract = "Mus musculus papillomavirus 1 (MmuPV1/MusPV1) induces persistent papillomas in immunodeficient mice but not in common laboratory strains. To facilitate the study of immune control, we sought an outbred and immunocompetent laboratory mouse strain in which persistent papillomas could be established. We found that challenge of SKH1 mice (Crl:SKH1-Hrhr) with MmuPV1 by scarification on their tail resulted in three clinical outcomes: (i) persistent (>2-month) papillomas (~20{\%}); (ii) transient papillomas that spontaneously regress, typically within 2 months (~15{\%}); and (iii) no visible papillomas and viral clearance (~65{\%}). SKH1 mice with persistent papillomas were treated by using a candidate preventive/therapeutic naked-DNA vaccine that expresses human calreticulin (hCRT) fused in frame to MmuPV1 E6 (mE6) and mE7 early proteins and residues 11 to 200 of the late protein L2 (hCRTmE6/mE7/mL2). Three intramuscular DNA vaccinations were delivered biweekly via in vivo electroporation, and both humoral and CD8 T cell responses were mapped and measured. Previously persistent papillomas disappeared within 2 months after the final vaccination. Coincident virologic clearance was confirmed by in situ hybridization and a failure of disease to recur after CD3 T cell depletion. Vaccination induced strong mE6 and mE7 CD8+ T cell responses in all mice, although they were significantly weaker in mice that initially presented with persistent warts than in those that spontaneously cleared their infection. A human papillomavirus 16 (HPV16)-targeted version of the DNA vaccine also induced L2 antibodies and protected mice from vaginal challenge with an HPV16 pseudovirus. Thus, MmuPV1 challenge of SKH1 mice is a promising model of spontaneous and immunotherapydirected clearances of HPV-related disease.",
keywords = "DNA vaccines, Mouse model, Neutralizing antibodies, Papillomavirus, SKH-1 mice, T cells",
author = "Jiang, {Rosie T.} and Wang, {Joshua W.} and Shiwen Peng and Huang, {Tsui Chin} and Chenguang Wang and Fabiana Cannella and Chang, {Yung Nien} and Viscidi, {Raphael P.} and Best, {Simon R.A.} and Hung, {Chien Fu} and Roden, {Richard B.S.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1128/JVI.00699-17",
language = "English",
volume = "91",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "15",

}

TY - JOUR

T1 - Spontaneous and vaccine-induced clearance of Mus musculus papillomavirus 1 infection

AU - Jiang, Rosie T.

AU - Wang, Joshua W.

AU - Peng, Shiwen

AU - Huang, Tsui Chin

AU - Wang, Chenguang

AU - Cannella, Fabiana

AU - Chang, Yung Nien

AU - Viscidi, Raphael P.

AU - Best, Simon R.A.

AU - Hung, Chien Fu

AU - Roden, Richard B.S.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Mus musculus papillomavirus 1 (MmuPV1/MusPV1) induces persistent papillomas in immunodeficient mice but not in common laboratory strains. To facilitate the study of immune control, we sought an outbred and immunocompetent laboratory mouse strain in which persistent papillomas could be established. We found that challenge of SKH1 mice (Crl:SKH1-Hrhr) with MmuPV1 by scarification on their tail resulted in three clinical outcomes: (i) persistent (>2-month) papillomas (~20%); (ii) transient papillomas that spontaneously regress, typically within 2 months (~15%); and (iii) no visible papillomas and viral clearance (~65%). SKH1 mice with persistent papillomas were treated by using a candidate preventive/therapeutic naked-DNA vaccine that expresses human calreticulin (hCRT) fused in frame to MmuPV1 E6 (mE6) and mE7 early proteins and residues 11 to 200 of the late protein L2 (hCRTmE6/mE7/mL2). Three intramuscular DNA vaccinations were delivered biweekly via in vivo electroporation, and both humoral and CD8 T cell responses were mapped and measured. Previously persistent papillomas disappeared within 2 months after the final vaccination. Coincident virologic clearance was confirmed by in situ hybridization and a failure of disease to recur after CD3 T cell depletion. Vaccination induced strong mE6 and mE7 CD8+ T cell responses in all mice, although they were significantly weaker in mice that initially presented with persistent warts than in those that spontaneously cleared their infection. A human papillomavirus 16 (HPV16)-targeted version of the DNA vaccine also induced L2 antibodies and protected mice from vaginal challenge with an HPV16 pseudovirus. Thus, MmuPV1 challenge of SKH1 mice is a promising model of spontaneous and immunotherapydirected clearances of HPV-related disease.

AB - Mus musculus papillomavirus 1 (MmuPV1/MusPV1) induces persistent papillomas in immunodeficient mice but not in common laboratory strains. To facilitate the study of immune control, we sought an outbred and immunocompetent laboratory mouse strain in which persistent papillomas could be established. We found that challenge of SKH1 mice (Crl:SKH1-Hrhr) with MmuPV1 by scarification on their tail resulted in three clinical outcomes: (i) persistent (>2-month) papillomas (~20%); (ii) transient papillomas that spontaneously regress, typically within 2 months (~15%); and (iii) no visible papillomas and viral clearance (~65%). SKH1 mice with persistent papillomas were treated by using a candidate preventive/therapeutic naked-DNA vaccine that expresses human calreticulin (hCRT) fused in frame to MmuPV1 E6 (mE6) and mE7 early proteins and residues 11 to 200 of the late protein L2 (hCRTmE6/mE7/mL2). Three intramuscular DNA vaccinations were delivered biweekly via in vivo electroporation, and both humoral and CD8 T cell responses were mapped and measured. Previously persistent papillomas disappeared within 2 months after the final vaccination. Coincident virologic clearance was confirmed by in situ hybridization and a failure of disease to recur after CD3 T cell depletion. Vaccination induced strong mE6 and mE7 CD8+ T cell responses in all mice, although they were significantly weaker in mice that initially presented with persistent warts than in those that spontaneously cleared their infection. A human papillomavirus 16 (HPV16)-targeted version of the DNA vaccine also induced L2 antibodies and protected mice from vaginal challenge with an HPV16 pseudovirus. Thus, MmuPV1 challenge of SKH1 mice is a promising model of spontaneous and immunotherapydirected clearances of HPV-related disease.

KW - DNA vaccines

KW - Mouse model

KW - Neutralizing antibodies

KW - Papillomavirus

KW - SKH-1 mice

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=85023188251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023188251&partnerID=8YFLogxK

U2 - 10.1128/JVI.00699-17

DO - 10.1128/JVI.00699-17

M3 - Article

VL - 91

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 15

M1 - e00699-17

ER -